Efficacy Data
nausea, vomiting
SECONDARY

Freedom from nausea for the first chemotherapy cycle.
Daily nausea (One of the secondary endpoints of this trial was to evaluate complete responses (ie, no vomiting and no use of rescue antiemetic treatments) between the 2 study arms. Complete response rates increased from 47% in the placebo arm to 55%% in the fosaprepitant arm (Upon completion of the first cycle of therapy, patients were allowed to continue to be treated with the antiemetic regimen that they received with their first cycle for up to 4 total cycles of chemotherapy. Seventy-one percent of patients in each arm agreed to continue with the antiemetic regimen that they initially received. The nausea scores for the subsequent 3 cycles, for the 2 study arms, showed similar patterns to what is observed in There was no suggestion that patients that received palonosetron, as opposed to ondansetron, had any improvement in outcomes regarding nausea (
